Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

Abstract Background Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent....

Full description

Bibliographic Details
Main Authors: Bettina Schenk, Stephanie Goerke, Ronny Beer, Raimund Helbok, Dietmar Fries, Mirjam Bachler
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Thrombosis Journal
Online Access:http://link.springer.com/article/10.1186/s12959-017-0158-9

Internet

http://link.springer.com/article/10.1186/s12959-017-0158-9

Similar Items